Anthropic Bets Big on Life Sciences Ahead of IPO

By Daniel Okafor

Nine of the 10 largest pharmaceutical companies and eight of the 10 largest healthcare companies in the Fortune 500 each spent at least $100,000 with Anthropic over a recent yearlong period. That claim sits in Anthropic's S-1 filing, and it frames the company's next act: life sciences, from biotech research to drug discovery.

The filing, which lays out Anthropic's finances and ambitions ahead of a massive initial public offering next month, reads as a life-sciences manifesto. Its second line says AI "could rapidly accelerate scientific innovation" and "bring cures for major diseases within reach." A page later, biological progress tops the company's list of ways it hopes AI will improve lives. Anthropic declined to comment on the story.

Why pharma fits the business model

Anthropic already won the coding market. Now it needs growth beyond software engineering tools. Life sciences promotes its most advanced, expensive models in an industry accustomed to spending billions on research and development. That is the mechanism: high-cost AI, sold to buyers who already pay premium prices for research.

The company makes the market case itself. "In the life sciences sector, where annual global pharmaceutical spend is expected to exceed $2 trillion in 2026, Claude is used in drug discovery and development by our customers, our biotechnology partners, and our own researchers," Anthropic writes in the filing.

What has Anthropic actually built?

The filing is not just vision. The company has spent money and hired:

• Claude Science, a product now in beta, launched in June.
• A molecular biology lab opened in the Bay Area this year.
• A $400 million all-stock acquisition of biotech startup Coefficient Bio in April.
• A new robotics standard, announced in August, that lets AI control lab equipment.
• Open life-sciences roles in chemistry, experimental biology and research engineering — two posted late this week offer $320,000 salaries to researchers who can design and manufacture antibodies.

Vas Narasimhan, CEO of Novartis, joined Anthropic's board in April.

Competition is already lined up. OpenAI has a competing offering called Rosalind. Google spinoff Isomorphic Labs plans to use AI to create cancer-beating drugs. The three companies will fight for the same research customers.

How deep does the Lilly deal go?

The S-1 touts Anthropic's work with Eli Lilly, the $1.3 trillion pharmaceutical giant. Lilly has 50,000 employees with access to a Claude enterprise account. More than 85% of them actively use the tool, according to the filing. That penetration rate gives Anthropic a reference customer for every other pharma sales pitch.

What drives Dario Amodei?

CEO Dario Amodei, a former theoretical physicist, has made life sciences a personal theme. In a September essay about "pacing" AI research, he said he had survived a cancer that would not have been treatable in the 1970s. His father died of a disease that was cured shortly after his death.

He first laid out the argument in a 2024 essay, "Machines of Loving Grace." "Biology is probably the area where scientific progress has the greatest potential to directly and unambiguously improve the quality of human life," Amodei wrote. He said he hopes AI-enabled research will prevent and treat all infectious diseases, eliminate most cancers, and double the human lifespan.

Ben Mann, co-leader of Anthropic's Labs organization, which built Claude Code, told Business Insider in August that his team has followed the CEO's lead. "Labs itself has shifted its focus from sort of more standard software engineering things to things like what Dario has described as curing all diseases like, Machines of Loving Grace-style," Mann said.

Does the public buy it?

Skeptics have data on their side. An Anthropic survey published from August found 91% of its staff believe AI will make a Nobel-level discovery by 2030, against 39% of US adults. No AI-designed drug has ever received FDA approval.

That gap defines the IPO pitch. Anthropic must convince investors that a market expected to top $2 trillion in 2026 will pay for Claude before regulators approve a single AI-designed therapy.